Overview Carisbamate Safety Study in Adult and Pediatric Subjects With Lennox-Gastaut Syndrome Status: Recruiting Trial end date: 2022-12-31 Target enrollment: Participant gender: Summary Open-label extension study from YKP509C001 to evaluate the safety and tolerability of carisbamate in subjects with Lennox-Gastaut Syndrome (LGS). Phase: Phase 1 Details Lead Sponsor: SK Life Science, Inc.